Efficacy and safety of oral decitabine/cedazuridine (astx727) in the cmml subpopulation from phase 2 and ascertain phase 3 studies

M. Savona, J. Mccloskey, E. Griffiths, K. Yee, A. Zeidan, A. Al-Kali,H. J. Deeg, P. Patel, M. Sabloff, M. -M. Keating, N. Zhu, N. Gabrail, S. Fazal, J. Maly, O. Odenike, H. Kantarjian, A. Dezern, C. O'Connell, G. Roboz, L. Busque, R. Buckstein, H. Amin, J. Randhawa, B. Leber, K. -H. Dao, Y. Sano, B. Mirakhur, H. Keer, G. Garcia-Manero

LEUKEMIA RESEARCH（2023）

引用 0|浏览1

暂无评分

关键词

MDS, oral decitabine/cedazuridine, oral, hypomethylating agent, CMML, phase II, phase III

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要